Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy
Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy
复制标题
甲状腺 Hurthle 细胞癌。
作者：
G. Har‐el;T. Hadar;K. Segal;R. Levy;J. Sidi
Hurthle细胞癌是一种罕见的甲状腺癌，在组织学上与甲状腺高分化恶性肿瘤相关。本文报告了对549例甲状腺癌患者中17例Hurthle细胞癌患者30年治疗经验的评价。17例患者均行手术治疗。6例（35.3%）死于甲状腺疾病。10年和15年生存率分别为63.7%和25%。这些发生率高于甲状腺高级别恶性肿瘤，低于甲状腺低级别恶性肿瘤。非手术治疗，包括放射性碘治疗，是令人失望的，因此，初步根治性手术是推荐的治疗选择。Cancer 57：1613-1617，1986.
Hurthle cell carcinoma is a rare thyroid cancer histologically related to the well‐differentiated malignancies of the thyroid gland. This report presents the evaluation of 30 years experience in treating 17 patients (out of 549 thyroid cancer patients) with Hurthle cell carcinoma. All 17 patients were treated surgically. Six patients (35.3%) died of their thyroid disease. Survival rates for 10 and 15 years were 63.7% and 25%, respectively. These rates are above those of high‐grade malignancies and below those of low‐grade malignancies of the thyroid gland. Nonsurgical treatment, including radioactive iodine therapy, is disappointing; thus, initial radical surgery is recommended as the treatment of choice. Cancer 57:1613–1617, 1986.